JAMA Study: Global Skin Cancer Burden Will Double by 2050

The global burden of skin cancer is on track to more than double by 2050, with the sharpest increases hitting low- and middle-income regions, according to a new JAMA Dermatology analysis published online May 13, 2026. The study models disability-adjusted life years (DALYs) for melanoma, cutaneous squamous cell carcinoma, and basal cell carcinoma using Global Burden of Disease 2023 data and a Bayesian age-period-cohort framework. **Key Takeaways** - Melanoma DALYs are projected to rise from 2 million in 2025 to more than 3.3 million by 2050. - Cutaneous squamous cell carcinoma DALYs are projected to more than triple, climbing from 1.2 million to 4.0 million. - Basal cell carcinoma DALYs are projected to approach 5 million globally by 2050, with the steepest increases concentrated in low- and middle-SDI regions. - Melanoma incidence surged more than 250% in East Asia and Andean Latin America between 1990 and 2023, while declining 10.5% in North America. The analysis, led by Youyou Zhou, MD, PhD, of the Department of Dermatology at Shenzhen People's Hospital and the Southern University of Science and Technology, reframes skin cancer from a high-income-country problem into a global trajectory. The projections imply roughly 12.3 million combined DALYs from the three skin cancers by 2050, compared with about 4.2 million at the 2025 baseline. ## The 33-Year Trend Behind the 2050 Projections The historical data driving the model spans 1990 through 2023. Across that window, all three skin cancers increased in low- and middle-SDI areas, the socio-demographic index used by Global Burden of Disease researchers to stratify regions by development. Melanoma rose more than 250% in East Asia and Andean Latin America, and rose substantially in Central Asia, North Africa, and the Middle East. High-SDI regions told a different story. North American melanoma DALYs declined 10.5% over the period, an outcome the authors attribute to decades of public health investment in sunscreen access, behavior change, and dermatologic screening. The divergence is the central finding. Where coordinated photoprotection campaigns took hold, melanoma trajectories bent down. Where they did not, every form of skin cancer climbed. The data give epidemiologic weight to behaviors that consumer skincare already encourages, including daily broad-spectrum SPF use and consistent reapplication, which SkinCareful has covered in the context of [the UV absorption science behind the two-hour rule](https://skincareful.care/science/how-often-to-reapply-sunscreen-science/). Keratinocyte cancers, the umbrella term for squamous and basal cell carcinoma, are responsible for most of the absolute projected growth. Combined, their 2050 DALYs are forecast to reach roughly 9 million, more than triple the 2.7 million 2025 baseline. The driver is cumulative ultraviolet exposure across population aging, not single high-dose burns. That mechanism is consistent with the molecular pathology of photodamage, which SkinCareful has detailed in its coverage of [how UV radiation degrades collagen and dermal proteins](https://skincareful.care/trends/uv-photoaging-mechanism-collagen-molecular-science/). ## What Do the 2050 Projections Mean for Daily Skincare? The JAMA data give population-level weight to a clinical position dermatologists already hold: broad-spectrum SPF, applied every day at adequate quantity and reapplied through UV exposure, is the single most evidence-backed intervention against skin cancer. The model implies that in regions where this behavior is sparse, every other skincare choice is downstream of a missing baseline. In regions where it is standard, the high-SDI melanoma decline shows the curve can bend. Practically, the findings sharpen three product-selection questions. The first is filter spectrum. UVA1 in particular drives photoaging and contributes to immunosuppression that may permit carcinogenesis, an issue SkinCareful examined in its analysis of [Mexoryl 400, the ultra-long UVA filter closing sunscreen's biggest gap](https://skincareful.care/trends/mexoryl-400-ultra-long-uva/). The second is delivery and consistency. Sunscreen efficacy collapses below recommended application densities, and reapplication behavior typically falls short of clinical-trial protocols. The third is adjunctive antioxidants, which neutralize the reactive oxygen species generated by residual UV penetration. Zhou's team flag a caveat clinicians and policymakers should not skip. Global Burden of Disease estimates likely underestimate true skin cancer load in low-SDI regions because of incomplete cancer registry coverage and limited dermatology infrastructure. The real 2050 number may be higher than 12.3 million DALYs. ## When Will Public Health Systems Respond to the Forecast? Skin cancer epidemiology operates on decade-long timescales, which limits how quickly any intervention can change the 2050 trajectory. Sunscreen behavior begun today will influence melanoma diagnoses in the 2040s and 2050s. The authors call for tiered investment in dermatology infrastructure across low- and middle-SDI regions, expanded sunscreen access, and primary-care training to identify suspicious lesions earlier, when keratinocyte cancers remain highly treatable. For consumers in high-SDI markets including the United States, the more immediate change is product-level. The U.S. Food and Drug Administration's ongoing implementation of the Modernization of Cosmetics Regulation Act, which SkinCareful previously covered in its analysis of [the FDA's MoCRA implementation update](https://skincareful.care/science/fda-mocra-cosmetics-implementation-update-2026/), is gradually narrowing the regulatory gap between U.S. and EU sunscreen frameworks, though the U.S. remains behind on next-generation UV filters. The next decade will determine whether the high-SDI melanoma decline holds or reverses, and whether the projected low-SDI surge can be partially blunted by behavior change and care access. The full JAMA Dermatology study by Zhou and colleagues is published in the journal's online-first section, with Medscape's clinical summary providing additional context. The Global Burden of Disease 2023 underlying dataset is available through the Institute for Health Metrics and Evaluation. ```json { "@context": "https://schema.org", "@type": "NewsArticle", "headline": "JAMA Study: Global Skin Cancer Burden Will Double by 2050", "description": "A May 2026 JAMA Dermatology study projects global skin cancer burden will more than double by 2050. What the melanoma, SCC, and BCC data mean for skincare.", "datePublished": "2026-05-14T09:30:00-04:00", "dateModified": "2026-05-14T09:30:00-04:00", "author": { "@type": "Person", "name": "SkinCareful News", "url": "https://skincareful.care/author/skincareful-news/" }, "publisher": { "@type": "Organization", "name": "SkinCareful", "url": "https://skincareful.care", "logo": { "@type": "ImageObject", "url": "https://skincareful.care/logo.png" } }, "image": "https://skincareful.care/images/articles/jama-global-skin-cancer-burden-2050.jpg", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://skincareful.care/science/jama-global-skin-cancer-burden-2050/" } } ```